A study of ovarian cancer biomarker amplification using ultrasound for early stage detection

Ultrasonics. 2014 Feb;54(2):451-4. doi: 10.1016/j.ultras.2013.05.014. Epub 2013 Jun 20.


The application of serum biomarker to ovarian tumors for early stage detection and clinical diagnosis is a rapidly expanding research area. The problem with conventional markers is that they are often released too late or at too low a level to be detected in time to trigger effective treatment. Ultrasound has been used to influence bio-effects in living cells, but there is only one reported case of the use of ultrasound to enhance the release of a biomarker (Carcinoembryonic antigen CEA). In this study we report the use of ultrasound to enhance the release of a combination of ovarian cancer biomarkers (CA125 and CA19-9) to help in the diagnosis of ovarian cancer at an early stage. The results indicated that after 5 min sonication at a frequency of 1 MHz and intensity of 0.3 W cm(-2), the CA125 and CA19-9 levels were increased by 2.02 and 4.21-fold respectively. These findings suggest that ultrasonic treatment can be used to enhance the release of serum biomarkers from ovarian tumors.

Keywords: Amplification; Biomarker; Ovarian cancer cell line; Ultrasound.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / metabolism*
  • CA-125 Antigen / metabolism*
  • CA-19-9 Antigen / metabolism*
  • Cell Line, Tumor
  • Female
  • Gene Expression Regulation, Neoplastic / radiation effects*
  • High-Energy Shock Waves
  • Humans
  • Membrane Proteins / metabolism*
  • Neoplasm Staging
  • Ovarian Neoplasms / metabolism*
  • Ovarian Neoplasms / pathology*
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Sonication / methods*


  • Biomarkers, Tumor
  • CA-125 Antigen
  • CA-19-9 Antigen
  • MUC16 protein, human
  • Membrane Proteins